Sellas' Phase 3 AML Trial Reaches 80th Death, Triggering Final Analysis

Bitget2026/10/28 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sellas Life Sciences' Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached its prespecified 80th death, triggering final analysis.
Preliminary topline results for the trial's primary endpoint of overall survival are expected this quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280835PRIMZONEFULLFEED9854999) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sellas' Phase 3 AML Trial Reaches 80th Death, Triggering Final Analysis

You may also like

Crypto prices